Previous 10 | Next 10 |
ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 third quarter on Thursday, November 11, 2021 before t...
ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its Genesis Robotic Magnetic Navigation (RMN) system at Princess Grace Hospital Center in...
ST. LOUIS, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the International Journal of Cardiology: Heart & Vascular demonstrating supe...
ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“ MicroPort EP ”) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electr...
Stereotaxis, Inc. (STXS) Q2 2021 Earnings Conference Call August 10, 2021 10:00 am ET Corporate Participants David Fischel - Chairman and Chief Executive Officer Kim Peery - Chief Financial Officer ConferenceCall Participants Adam Maeder - Piper Sandler Josh Jennings - Cowen Frank Takkinen - ...
Image source: The Motley Fool. Stereotaxis (NYSEMKT: STXS) Q2 2021 Earnings Call Aug 10, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Stereotaxis (STXS) Q2 2021 Earnings Call Transcript
ST. LOUIS, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2021. “Renewed global adoption of rob...
ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as ...
ST. LOUIS, July 20, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 second quarter on Tuesday, August 10, 2021 before the...
Palm Beach, FL – June 30, 2021 – Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and much research is devoted to this market. AF is responsible for most arrhythmia-related hospitalizations and leads to the greatest length of hospital stay associated w...
News, Short Squeeze, Breakout and More Instantly...
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Gene...
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation...
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac ...